Literature DB >> 11426336

Modulation of neuronal survival and axonal growth in vivo by tetracycline-regulated neurotrophin expression.

A Blesch1, J M Conner, M H Tuszynski.   

Abstract

Vector systems for the regulated and reversible expression of therapeutic genes are likely to improve the safety and efficacy of gene therapy for medical disease. In the present study, we investigated whether the expression of genes transferred into the central nervous system by ex vivo gene therapy can be regulated in vivo leading to controlled neuronal survival and axonal growth. Primary rat fibroblasts were transfected with a retrovirus containing a tetracycline responsive promoter for the expression of the neurotrophin nerve growth factor (NGF) or green fluorescent protein as a control (GFP). After lesions of basal forebrain cholinergic neurons, NGF-mediated neuronal rescue and axonal growth could be completely controlled over a 2-week period by the addition or removal of the tetracycline modulator doxycycline in the animals' drinking water. Further, continued expression of the reporter gene GFP could be reliably and repeatedly turned on and off in the injured CNS for at least 3 months post-grafting, the longest time point investigated. These data constitute the first report of regulated neuronal rescue and axonal growth by controlled neurotrophin gene delivery and long-term, regulated expression using ex vivo CNS gene therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11426336     DOI: 10.1038/sj.gt.3301480

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  8 in total

Review 1.  Anterograde transport of neurotrophic factors: possible therapeutic implications.

Authors:  Matteo Caleo; Maria Cristina Cenni
Journal:  Mol Neurobiol       Date:  2004-04       Impact factor: 5.590

Review 2.  Gene therapy in clinical medicine.

Authors:  S M Selkirk
Journal:  Postgrad Med J       Date:  2004-10       Impact factor: 2.401

3.  Gene delivery to the spinal cord: comparison between lentiviral, adenoviral, and retroviral vector delivery systems.

Authors:  Ahmed A Abdellatif; Jennifer L Pelt; Richard L Benton; Russell M Howard; Pantelis Tsoulfas; Peipei Ping; Xiao-Ming Xu; Scott R Whittemore
Journal:  J Neurosci Res       Date:  2006-08-15       Impact factor: 4.164

4.  Survival and regeneration of rubrospinal neurons 1 year after spinal cord injury.

Authors:  Brian K Kwon; Jie Liu; Corrie Messerer; Nao R Kobayashi; John McGraw; Loren Oschipok; Wolfram Tetzlaff
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

5.  A novel inducible tyrosine kinase receptor to regulate signal transduction and neurite outgrowth.

Authors:  Ronald W Alfa; Mark H Tuszynski; Armin Blesch
Journal:  J Neurosci Res       Date:  2009-09       Impact factor: 4.164

Review 6.  Cell therapy for spinal cord regeneration.

Authors:  Stephanie M Willerth; Shelly E Sakiyama-Elbert
Journal:  Adv Drug Deliv Rev       Date:  2007-10-05       Impact factor: 15.470

7.  Immune-evasive gene switch enables regulated delivery of chondroitinase after spinal cord injury.

Authors:  Emily R Burnside; Fred De Winter; Athanasios Didangelos; Nicholas D James; Elena-Cristina Andreica; Hugo Layard-Horsfall; Elizabeth M Muir; Joost Verhaagen; Elizabeth J Bradbury
Journal:  Brain       Date:  2018-08-01       Impact factor: 13.501

Review 8.  In vivo gene regulation using tetracycline-regulatable systems.

Authors:  Knut Stieger; Brahim Belbellaa; Caroline Le Guiner; Philippe Moullier; Fabienne Rolling
Journal:  Adv Drug Deliv Rev       Date:  2009-04-23       Impact factor: 15.470

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.